Publications

Our team is dedicated to the continuing study and education of emerging viruses

Repurposing Probenecid to Inhibit SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus (RSV) Replication

Ralph A. Tripp and David E. Martin 

In vitro and in vivo identification of clinically approved drugs that modify ACE2 expression

Sanju Sinha †,‡, Kuoyuan Cheng †,‡, Alejandro A Schäffer ‡, Kenneth Aldape ‡, Eyal Schiff & Eytan Ruppin

Probenecid inhibits SARS‑CoV‑2 replication in vivo and in vitro

Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still & Ralph A. Tripp

Targeting Organic Anion Transporter 3 with Probenecid as a Novel Anti-Influenza A Virus Strategy

Olivia Perwitasari, Xiuzhen Yan, Scott Johnson, Caleb White, Paula Brooks, S. Mark Tompkins, Ralph A. Tripp

Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication

Jackelyn Murray, Harrison C. Bergeron, Les P. Jones, Zachary Beau Reener, David E. Martin, Fred D. Sancilio and Ralph A. Tripp

The Pathophysiology of COVID-19 and SARS-CoV-2 Infection

Leigh Anne Swayne, Scott R. Johnstone, Chen Seng Ng, Juan C. Sanchez-Arias,
Miranda E. Good, Silvia Penuela, Alexander W. Lohman, Abigail G. Wolpe, Victor E. Laubach, Michael Koval, and Brant E. Isakson